Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Double-blind, Placebo-controlled Study of Oral Almotriptan Malate (AXERT®) 6.25 mg, 12.5 mg, and 25 mg in the Acute Treatment of Migraine in Adolescents

NCT00210483 is registered in ClinicalTrials.gov with Janssen-Ortho LLC as lead sponsor.

NCT NCT00210483
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00210483 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Double-blind, Placebo-controlled Study of Oral Almotriptan Malate (AXERT®) 6.25 mg, 12.5 mg, and 25 mg in the Acute Treatment of Migraine in Adolescents
Lead sponsor
Janssen-Ortho LLC
Phase
Phase 3
Overall status
Completed
Start date
July 31, 2003
Completion date
July 31, 2005
Enrollment
866 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

migraine